Menu

Top Stories

Published on Wednesday, April 20, 2016

Kevin Shroyer, father of Alpha lung donor, completes Boston Marathon

Kevin Shroyer, father of Alpha lung donor, completes Boston Marathon

Kevin Shroyer, the father of a 14-year-old girl whose donated lungs saved an Alpha’s life, completed the Boston Marathon on Monday, April 18 in her honor.

Kevin Shroyer

Although the experienced distance runner was happy to cross the finish line, he said he would like to post a faster time next year. He qualified for the event by completing a previous marathon in three hours and 35 minutes, but finished on Monday in 4:01.

"Since it was not what I was expecting to run, I will let everyone know what happened,” he wrote Monday on his Facebook page. “I was pretty much right on my pace upon climbing the infamous Heartbreak Hill. However, upon descending the back side, my right quad seized up suddenly, forcing me to come to a dead stop and grab onto a handrail to keep from falling.

“Fortunately, I was running close to the side of the road at the time. A sweet older woman spectator immediately saw the distress I was in as I could not straighten that leg out below the knee. She held onto me until the pain subsided and I was able to gradually massage it until it released, but my day was effectively over at that point.”

Calling it a “frustrating and humbling” experience, Shroyer struggled over the last six miles, alternating between fast walking and very slow running.

“This was something that had NEVER happened to me before in a race,” he wrote. “However, I accomplished goal #1 and that was to qualify, run, and finish the race for Korinne and to promote organ, tissue and eye donation on the biggest running stage in the world! It wasn't my plan to be out there for 4:01, but perhaps it was God's plan.

“Timewise, this was my worst marathon in years. But, maybe by me being out there all those additional minutes, someone was impacted by seeing Korinne's picture on the back of my singlet and the fact that she was an organ and tissue donor. Indeed, I had a number of other runners, male and female, offer expressions of condolence to me throughout the day, which was nice. So, if that is the one positive takeaway from today's experience, then I can accept that and would do it all over again!”

Shroyer has already qualified for the 2017 Boston Marathon, and he plans to run it.

“After looking at today's result they might not want me back, but too bad, I am coming!” he said. “Today will not be my defining Boston moment!"

To read about how Shroyer prepared for the Boston Marathon, click here.


Print

The Annual Alpha-1 National Conference: The largest gathering of Alphas

Tuesday, June 18, 2019
The city of Orlando, Florida, will be the site of the largest gathering of Alphas, caregivers, family members, researchers, industry representatives, and the Alpha-1 community at large, to date, as the Alpha-1 Foundation holds its 28th Annual...
Divider

CSL Behring initiates voluntary recall for 4 lots of Zemaira

Thursday, June 6, 2019
The Alpha-1 Foundation was informed by CSL Behring that a Voluntary Biological Product Recall is being initiated for 4 lots of Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency...
Divider

Here’s the “Scoop” on the Iowa Walk

Tuesday, June 4, 2019
Filled with families, friends, laughter and of course, ice cream, the Iowa Alpha-1 Get the Scoop Walk is one not to be missed. Like most walks, it was started with a small group, and now, 11 years later, this walk has become one of the most...
Divider

Alpha-1 Hero Walk raises funds and awareness for Alpha-1

Thursday, May 23, 2019
The 9th Annual Alpha-1 Hero Walk took place on May 4th, in Richmond, VA, where 75 attendees walked to raise awareness and funds for Alpha-1 Antitrypsin Deficiency (Alpha-1) research and related programs, exceeding $11,000. Pamela VanScoy, Walk...
Divider

Alpha-1 Foundation celebrates the 2019 research grants

Tuesday, May 21, 2019
The Alpha-1 Foundation (A1F) hosted a reception on Monday, May 20, 2019, to honor the newly awarded research grant recipients, where 158 guests joined at the Perot Museum in Dallas, Texas, in conjunction with the 2019 American Thoracic...
Divider

New method could help find potential treatments for rare diseases

Monday, May 20, 2019
Finding treatments for rare diseases is difficult: because they affect such a small number of people, research funding and other resources may be limited. Even if researchers are interested in studying a rare disease, the methods for testing...
Divider

Celebration of Life 2019: “Alpha-1 Derby: Betting on the cure”

Friday, May 10, 2019
On Monday, April 29th, the Alpha-1 Foundation welcomed friends, family, physicians, researchers, and industry partners to the 19th Annual Celebration of Life, the Foundation’s signature fundraising event in Miami Beach, Florida. The event is...
Divider

Funding for NIH increased after House Appropriations Committee approves funding bill

Friday, May 10, 2019
The House Appropriations Committee approved the fiscal year 2020 Labor, Health and Human Services, Education, and Related Agencies bill, on Wednesday, May 8, 2019. The legislation includes funding for programs within the Departments of Labor,...
Divider

NORD releases principles to lower the cost of prescription drugs

Wednesday, May 8, 2019
The National Organization for Rare Disorders (NORD), which represents the 25-30 million Americans living with rare disorders, including Alpha-1 Antitrypsin Deficiency (Alpha-1), announced its development of key drug pricing principles,...
Divider

Alpha-1 Foundation attends Coalition of Patient Advocacy Groups (CPAG) Meeting

Tuesday, May 7, 2019
The Alpha-1 community was well represented as the Alpha-1 Foundation attended the Coalition of Patient Advocacy Groups (CPAG) Meeting, in Rockville, MD, on April 30, 2019. Photo (left to right): Jamie Sullivan, COPD Foundation; David Fernandez,...
Divider

FDA approves new, larger vial sizes for Alpha-1 augmentation therapy

Thursday, April 25, 2019
The U.S. Food and Drug Administration (FDA) has approved single-vial dosing (4-gram and 5-gram vial sizes) for ZEMAIRA® [Alpha1-Proteinase Inhibitor] for augmentation therapy, the current treatment for Alpha-1 Antitrypsin Deficiency (Alpha-1)...
Divider

Alpha-1 Foundation co-sponsors congressional reception for the NHLBI Division of Lung Diseases

Wednesday, April 17, 2019
On April 9, 2019, the Alpha-1 Foundation was proud to be a co-sponsor of the congressional reception to celebrate the 50th anniversary of the Division of Lung Diseases of the National Heart, Lung and Blood Institute (NHLBI), an institute of the...
Divider
12345678910Last

Article Search

Enter keywords in text box and click Search button for results.

Archive